An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) (clinicaltrials.gov) - Sep 15, 2026 - P1/2 | N=30 | Completed | Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex | Active, not recruiting ➔ Completed
Trial completion • Anemia • Autoimmune Hemolytic Anemia • Complement-mediated Rare Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura
|